A Study to Evaluate Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Participants

Inclusion Criteria: * Subject diagnosed with IA or IM. A positive diagnosis is defined as follows: * Proven, probable or possible IFI per the European Organisation for Research and Treatment of Cancer/Mycoses Study Group \[EORTC/MSG\], 2008 criteria Note: Subjects with "possible" IFI will be eligible for enrollment; however, diagnostic tests to confirm the invasive fungal disease as "probable" or "proven" according to the EORTC/MSG criteria should be completed within 10 calendar days after the first dose of study drug * Note: In addition to the criteria set for mycological criteria by the EORTC/MSG in 2008, and only for subjects with an underlying hematologic malignancy or recipients of hematopoietic stem cell transplant (HSCT) who also have clinical and radiologic features consistent with invasive fungal infection, the following are acceptable: * Galactomannan (GM) levels (optical density index) meeting the below criteria are acceptable mycological evidence for enrollment or upgrading the diagnosis to probable IA: * 1\. A single value for serum or bronchoalveolar lavage (BAL) fluid of ≥ 1.0 or * 2\. Two serum GM values of ≥ 0.5 from two separate samples * Subject has sufficient venous access to permit intravenous administration of study drug or the ability to swallow oral capsules * A female subject is eligible to participate if not pregnant and at least one of the following conditions applies: * Not a subject who is of childbearing potential, OR * Subject w…